Can lung cancer patients safely stop immunotherapy after 6 months?

NCT ID NCT03469960

Completed Disease control Sponsor: Intergroupe Francophone de Cancerologie Thoracique Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tested whether patients with advanced non-small cell lung cancer (NSCLC) who received initial immunotherapy (nivolumab and ipilimumab) for 6 months could safely stop treatment and be monitored, instead of continuing therapy indefinitely. The study enrolled 265 patients with PD-L1 positive stage IV NSCLC. The goal was to see if stopping treatment was as effective at controlling cancer while reducing side effects and improving quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Nivolumab and Ipilimumab (immunotherapy drugs)
What this could lead to: If successful, this could show that stopping immunotherapy after 6 months is as effective as continuing indefinitely, reducing side effects and improving quality of life.
What could go wrong: This is a completed trial, but results may not apply to all patients. Stopping treatment early could risk disease progression in some individuals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER METASTATIC

Contacts and locations

Locations

AP-HP Hopital Tenon - Pneumologie

Paris, 75020, France
AP-HP Hôpital Bichat

Paris, France
Amiens - CHU

Amiens, France
Angers - CHU

Angers, 49000, France
Annecy - CH

Annecy, 74374, France
Argenteuil -CH

Argenteuil, 95100, France
Avignon - CH

Avignon, France
Bordeaux - Polyclinique Nord

Bordeaux, France
Boulogne - Ambroise Paré

Boulogne-Billancourt, France
CH

Cholet, France
CH Chambery

Chambéry, France
CH Lyon Sud - Pneumologie

Lyon, France
CH de Chauny

Chauny, France
CH de Pontoise

Cergy-Pontoise, France
CH de Villefranche - Pneumologie

Villefranche, France
CHRU Grenoble

Grenoble, France
CHRU de Lille

Lille, France
CHRU de Tours

Tours, France
CHU Nîmes

Nîmes, France
CHU Toulouse

Toulouse, France
CHU de Limoges

Limoges, France
Caen - CHU Côte de Nacre

Caen, 14000, France
Cahors - CH

Cahors, 46000, France
Centre Antoine Lacassagne

Nice, France
Centre Hospitalier - Pneumologie

Le Mans, 72000, France
Centre René Huguenin

Saint-Cloud, France
Clamart - Hôpital Percy

Clamart, 92140, France
Clermont Ferrand - CHU

Clermont-Ferrand, 63000, France
Colmar - CH

Colmar, 68000, France
Dijon - CAC

Dijon, 21000, France
GH Paris Saint-Joseph

Paris, France
HIA Begin

Saint-Mandé, France
Hôpital Saint Louis APHP

Paris, France
ICL Lucien Neuwirth

Saint-Priest-en-Jarez, France
Institut Paoli Calmette

Marseille, France
La Roche Sur Yon - CH

La Roche-sur-Yon, 85925, France
Marseille - Hôpital Européen

Marseille, France
Mont de Marsan - CH

Mont-de-Marsan, 40000, France
Mulhouse - CH

Mulhouse, 68000, France
Nantes - Centre René Gauducheau

Nantes, 44805, France
Orléans - CH

Orléans, 45000, France
Paris - Institut Curie

Paris, France
Rouen - CHU

Rouen, 76000, France
Saint Quentin - CH

Saint-Quentin, 02100, France
Suresnes - Hopital Foch

Suresnes, 92151, France
Toulon - CHI

Toulon, 83000, France
Versailles - CH

Versailles, 78157, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.